26
|
Perdrizet K, Stockley T, Law J, Shabir M, Zhang T, Le L, Lau A, Tsao M, Kamel-Reid S, Pal P, Cabanero M, Schwock J, Ko H, Liu G, Bradbury P, Sacher A, Shepherd F, Leighl N. P1.01-30 Non-Small Cell Lung Cancer (NSCLC) Next Generation Sequencing (NGS): Integrating Genomic Sequencing into a Publicly Funded Health Care Model. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
27
|
Xu J, Patassini S, Rustogi N, Riba-Garcia I, Hale BD, Phillips AM, Waldvogel H, Haines R, Bradbury P, Stevens A, Faull RLM, Dowsey AW, Cooper GJS, Unwin RD. Regional protein expression in human Alzheimer's brain correlates with disease severity. Commun Biol 2019; 2:43. [PMID: 30729181 PMCID: PMC6361956 DOI: 10.1038/s42003-018-0254-9] [Citation(s) in RCA: 113] [Impact Index Per Article: 22.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Accepted: 12/03/2018] [Indexed: 01/18/2023] Open
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that currently affects 36 million people worldwide with no effective treatment available. Development of AD follows a distinctive pattern in the brain and is poorly modelled in animals. Therefore, it is vital to widen the spatial scope of the study of AD and prioritise the study of human brains. Here we show that functionally distinct human brain regions display varying and region-specific changes in protein expression. These changes provide insights into the progression of disease, novel AD-related pathways, the presence of a gradient of protein expression change from less to more affected regions and a possibly protective protein expression profile in the cerebellum. This spatial proteomics analysis provides a framework which can underpin current research and open new avenues to enhance molecular understanding of AD pathophysiology, provide new targets for intervention and broaden the conceptual frameworks for future AD research.
Collapse
|
28
|
Moraes F, Weiss J, Moskovitz M, Sorotsky H, Pintilie M, Leighl N, Bradbury P, Liu G, Zadeh G, Doherty M, Kia A, So J, Cabanero M, Pugh T, Sugumar V, Torti D, Tsao M, Torchia J, Shultz D, Shepherd F, Lok B. MA25.11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
29
|
Graham D, Chen E, Pisters K, Bradbury P, Trinkaus M, Chan M, Arif S, Zurawska U, Rothenstein J, Zawisza D, Effendie S, Sawczak M, Leighl N. P1.01-54 A Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.610] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
30
|
Perdrizet K, Stockley T, Tsao M, Morganstein J, Kamel-Reid S, Ranich L, Shepherd F, Bradbury P, Liu G, Hwang D, Pal P, Schwock J, Boerner S, Sacher A, Law J, Leighl N. P2.03-03 Upfront Next Generation Sequencing in NSCLC: A Publicly Funded Perspective. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
31
|
Ezeife D, Morganstein J, Lau S, Law J, Le L, Bradbury P, Liu G, Shepherd F, Leighl N. MA14.06 Predictors of Financial Toxicity, an Under-Recognized Patient-Reported Outcome. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
32
|
Jiang S, Hurry M, Hueniken K, Brown M, Liang M, Patel D, Labbe C, Eng L, Naik H, Bradbury P, Leighl N, Shepherd F, Xu W, Liu G, Walton R, O'Kane G. MA18.09 Predictors of Health Utility Scores (HUS) in Advanced EGFR-Mutated NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.471] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Eng L, Liu S, Farzanfar D, Alton D, Smith E, Mccartney A, Yeung S, Basgaran A, Balaratnam K, Mattina K, Harper C, Mohan R, Brown M, Hope A, Bradbury P, Sacher A, Leighl N, Shepherd F, Bezjak A, Howell D, Jones J, Xu W, Goldstein D, Evans W, Selby P, Giuliani M, Liu G. MA18.07 Awareness of the Harms of Continued Smoking Among Lung Cancer (LC) Survivors. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
34
|
Hueniken K, Hurry M, Jiang S, Labbe C, Brown M, Eng L, Naik H, Liang M, Patel D, Bradbury P, Leighl N, Shepherd F, Xu W, O'Kane G, Walton R, Liu G. P1.13-11 PRO-CTCAE Toxicities in Advanced NSCLC Patients with EGFR Mutations: A Real World Assessment. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
35
|
Lee M, Kuehne N, Hueniken K, Sorotsky H, Liang M, Patel D, Cheng D, Chen Z, Eng L, Brown M, Cho J, Leighl N, De Perrot M, Reisman D, Xu W, Bradbury P, Liu G. P2.06-23 Association of Two BRM Promoter Polymorphisms and Tobacco Exposure with Malignant Pleural Mesothelioma (MPM) Risk and Survival. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
36
|
Sung M, Zer A, Walia P, Khoja L, Maganti M, Labbe C, Shepherd F, Bradbury P, Liu G, Leighl N. P3.04-20 Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1727] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
37
|
Cho J, Bradbury P, Patsios D, Keshavjee S, Leighl N, Hope A, De Perrot M. P3.09-007 Thoracic Asymmetry and Its Impact on Survival after Radiation and Surgery for Malignant Pleural Mesothelioma. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
38
|
Juergens R, Hao D, Laurie S, Ellis P, Mates M, Bradbury P, Tehfe M, Kollmannsberger C, Arnold A, Goffin J, Wheatley-Price P, Hilton J, Robinson A, Tu D, Brown-Walker P, Seymour L. MA 10.01 Durvalumab ± Tremelimumab with Platinum-Doublets in Non-Small Cell Lung Cancer: Canadian Cancer Trials Group Study IND.226. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
39
|
Karim S, Ding K, Bradbury P, Ellis P, Mittman N, Xiaoqun Sun X, Millward M, Liu G, Sun S, Stockler M, Cohen V, Blais N, Sangha R, Boyer M, Sasidharan R, Lee C, Shepherd F, Goss G, Seymour L, Leighl N. Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx375.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Leighl N, Kuo J, Pavel A, Prescilla M, Shepherd F, Liu G, Bradbury P, Moskovits M. Treatment beyond disease progression: ALK inhibitors in ALK-rearranged advanced NSCLC. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Hao D, Juergens R, Laurie S, Mates M, Tehfe M, Bradbury P, Kollmannsberger C, Ellis P, Hilton J, Brown-Walker P, Seymour L. A Canadian Cancer Trials Group phase IB study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226). Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32882-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
42
|
|
43
|
Bradbury P, Meyer R, Pater J, Tu D, Seymour L, Shepherd L, Eisenhauer E. Stopping a trial early in oncology: for patients or for industry? Ann Oncol 2009; 20:395-6. [DOI: 10.1093/annonc/mdn753] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Mackay HJ, Bradbury P, Asomaning K, Zhou W, Kulke M, Su L, Suk Heist R, Lynch TJ, Christiani DC, Liu G. Stage and histology influence the relationship between MDM2 promoter polymorphism and esophageal cancer and overall survival (OS). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.21047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
21047 Background: A single nucleotide polymorphism in the MDM2 promoter (SNP309) has been found to affect OS of advanced stage gastric adenocarcinoma (AD) and early stage squamous (SQ) cell carcinoma of the lung. The aim of this study was to evaluate the role of this polymorphism in the prognosis of esophageal cancer, another aerodigestive cancer. Methods: 150 early stage (E) and 118 locally advanced stage (LA) esophageal cancers were genotyped for MDM2 SNP309 using Taqman. The primary endpoint was overall survival (OS). Results: E disease: n=23 stage I; n=127 stage II. LA disease: n=93, Stage III; n=25, Stage IVA. AD comprised 215 (81%), while SQ comprised 45 (17%) of cases; 8 (3%) had poorly differentiated tumors. Median follow-up = 32 months. Median OS were 36 and 21 months for E and LA disease, respectively. Both histology and disease stage affected the relationship between SNP309 and esophageal cancer OS (see Table ). The wildtype T/T genotype conferred a worse OS in E patients (log-rank, p=0.03), especially those with AD (log-rank, p=0.003). In Cox proportional hazards interaction analyses, after adjusting for age, gender, stage and PS, there were statistically significant interactions between MDM2 SNP309 and disease stage (interaction p=0.004) and between MDM2 SNP309 and histologic subtype (AD vs. SQ)(interaction p=0.02). Thus, the direction of SNP309 association from our AD and E esophageal cancer patients are opposite to those of our SQ and LA esophageal cancer patients. However, our SQ and LA results are similar to the SQ lung cancer and advanced stage gastric cancers previously reported. This suggests that biologic mechanisms underpinning the prognostic role of SNP309 are dependent on extent of disease and histologic subtype. Conclusion: Histology and disease stage interact with the prognostic role of MDM2 SNP309 polymorphism in esophageal cancer OS. [Table: see text] No significant financial relationships to disclose.
Collapse
|
45
|
Bradbury P, Lang B, Vincent A, Han C, Talbot D. A prospective study of the incidence of sub-clinical Lambert-Eaton Myasthenic Syndrome (LEMS) in patients with small cell lung cancer (SCLC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Wall L, Talbot DC, Bradbury P, Jodrell DI. A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. Br J Cancer 2004; 90:800-4. [PMID: 14970856 PMCID: PMC2410175 DOI: 10.1038/sj.bjc.6601594] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
BB-3644 is an oral, broad-spectrum matrix metalloproteinase inhibitor (MMPI) structurally related to marimastat and BB-94. It is also >10-fold more active than marimastat in inhibiting the processing of cell-bound TNF-alpha. Preclinical studies suggested a favourable toxicity profile when compared to marimastat, and therefore it was selected for clinical evaluation. Patients with advanced solid tumours against which established treatments had failed, or for which no satisfactory treatment exists and of good performance status, were eligible. Treatment consisted of twice daily (bd) oral BB-3644 for 84 days. The initial dose was 5 mg bd, and subsequent cohorts were treated with 10, 20 and 30 mg bd. In all, 22 patients were enrolled. The dose-limiting toxicity (DLT) was musculoskeletal pain. For 28 days of treatment with BB-3644, 20 mg bd was the maximum tolerated dose (MTD), as at 30 mg bd, six of nine patients developed significant musculoskeletal toxicity by day 28. Following chronic oral dosing (>28 days) with BB-3644, three of five patients treated at 10 mg bd developed musculoskeletal DLT by day 84, defining the MTD as 5 mg bd. As dose-limiting musculoskeletal toxicity was encountered at doses of BB-3644 unlikely to provide an advantage over currently available MMPIs, further evaluation is not recommended.
Collapse
|
47
|
Bradbury P, Mann CJ, Köchl S, Anderson TA, Chester SA, Hancock JM, Ritchie PJ, Amey J, Harrison GB, Levitt DG, Banaszak LJ, Scott J, Shoulders CC. A common binding site on the microsomal triglyceride transfer protein for apolipoprotein B and protein disulfide isomerase. J Biol Chem 1999; 274:3159-64. [PMID: 9915855 DOI: 10.1074/jbc.274.5.3159] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The assembly of triglyceride-rich lipoproteins requires the formation in the endoplasmic reticulum of a complex between apolipoprotein B (apoB), a microsomal triglyceride transfer protein (MTP), and protein disulfide isomerase (PDI). In the MTP complex, the amino-terminal region of MTP (residues 22-303) interacts with the amino-terminal region of apoB (residues 1-264). Here, we report the identification and characterization of a site on apoB between residues 512 and 721, which interacts with residues 517-603 of MTP. PDI binds in close proximity to this apoB binding site on MTP. The proximity of these binding sites on MTP for PDI and amino acids 512-721 of apoB was evident from studies carried out in a yeast two-hybrid system and by co-immunoprecipitation. The expression of PDI with MTP and apoB16 (residues 1-721) in the baculovirus expression system reduced the amount of MTP co-immunoprecipitated with apoB by 73%. The interaction of residues 512-721 of apoB with MTP facilitates lipoprotein production. Mutations of apoB that markedly reduced this interaction also reduced the level of apoB-containing lipoprotein secretion.
Collapse
|
48
|
Mann CJ, Anderson TA, Read J, Chester SA, Harrison GB, Köchl S, Ritchie PJ, Bradbury P, Hussain FS, Amey J, Vanloo B, Rosseneu M, Infante R, Hancock JM, Levitt DG, Banaszak LJ, Scott J, Shoulders CC. The structure of vitellogenin provides a molecular model for the assembly and secretion of atherogenic lipoproteins. J Mol Biol 1999; 285:391-408. [PMID: 9878414 DOI: 10.1006/jmbi.1998.2298] [Citation(s) in RCA: 153] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The assembly of atherogenic lipoproteins requires the formation in the endoplasmic reticulum of a complex between apolipoprotein (apo)B, a microsomal triglyceride transfer protein (MTP) and protein disulphide isomerase (PDI). Here we show by molecular modelling and mutagenesis that the globular amino-terminal regions of apoB and MTP are closely related in structure to the ancient egg yolk storage protein, vitellogenin (VTG). In the MTP complex, conserved structural motifs that form the reciprocal homodimerization interfaces in VTG are re-utilized by MTP to form a stable heterodimer with PDI, which anchors MTP at the site of apoB translocation, and to associate with apoB and initiate lipid transfer. The structural and functional evolution of the VTGs provides a unifying scheme for the invertebrate origins of the major vertebrate lipid transport system.
Collapse
|
49
|
Kropotov AV, Yau P, Bradbury P, Tomilin NV. [Nonhistone chromosome proteins HMG1 and HMG2 stabilize one of the sequence-specific complexes, formed on the promotor of human retroposons of the ALU-family of other nuclear proteins]. MOLEKULIARNAIA GENETIKA, MIKROBIOLOGIIA I VIRUSOLOGIIA 1997:32-6. [PMID: 9411219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Human retroposons of the Alu family have an internal promoter for RNA polymerase III also present in tRNA genes, but Alu are poorly transcribed by this polymerase in somatic cells in vivo, which is probably due to an efficient system of repression of the Alu transcription. The key control promoter element of the tRNA genes, known as B-box, binds basal transcription factor TFIIIC2, which initiates assembly of the full transcription complex. Previously we identified several human nuclear factors which bind to Alu Subregion covering B-box and the adjacent sequences, which can be involved in repression of Alu transcription. In this study we identified one factor, F1, as HMF1/2 and another factor, F2, as TFIIIC2-like protein reacting with B-box. Both the factors are not alu-specific, whereas the third identified Alu-binding factor, F3, seems to be specific for the Alu-specific subsequence located just downstream from B-box and can discriminate evolutionary "young" and "old" Alu subfamilies producing different numbers of transcripts in vivo. Although HMG1/2 binds to Alu in a sequence-unspecific manner, the proteins are capable of stabilizing the sequence-specific complex F3 which can be functionally significant. We believe that the factors binding to Alu B-box subregion interfere somehow with the functions of the basal factor TFIIIC2 and, hence, can be co-repressors of Alu transcription by RNA polymerase III.
Collapse
|
50
|
Abstract
A 62-year-old man with acquired Brown's syndrome is presented. This was due to an orbital metastatic deposit, a cause not previously reported. Other causes of this disorder and its treatment are discussed.
Collapse
|